A registered PHASE4 study indexed because it matched monitored longevity research terms. Registry status: Terminated. Registration does not establish safety or effectiveness.
What the source actually supports
- Evidence stage
- Phase 4
- Study design
- NA · SINGLE GROUP · TREATMENT · NONE
- Evidence population
- Human clinical study registration
- Participants
- 16
- Population
- ALL · 50 Years
- Duration
- 2020-07-20 to 2021-11-22
- Intervention
- Brolucizumab 6 mg solution for intravitreal injection
- Comparator
- Not reported
- Outcomes measured
- The primary outcome is the mean maximum treatment interval with intravitreal brolucizumab at month 6 and 12. — up to mo…; Best corrected visual acuity (BCVA) in letters — month 6 and 12; Number of brolucizumab intravitreal treatments applied during the 12 months study period. — 12 months; Central retinal thickness (CRT, in µm) as measured in the central ETDRS subfield Spectral-Domain Optical coherence tomo…; Presence of qualitative SD-OCT features like intraretinal fluid, subretinal fluid, pigment epithelial detachment and hy…; Total CNV area and vessel density as measured by OCTangiography (OCTA) at baseline, month 6 and 12. — month 6 and 12; Total area of leakage from CNV — baseline and month 12; VFQ-25 total evaluated by quality of life questionnaire VFQ-25 at baseline and month 6 and 12. — month 6 and 12; Rates of adverse events and serious adverse events at 6 and 12 months. — 6 and 12 months.; BCVA change (letters) from baseline (=switch to brolucizumab) — month 6 and 12; the total lesion area as evaluated by Fluorescein angiography (FA) at baseline and month 12 — baseline and month 12; VFQ-25 subscores — month 6 and 12
- Reported result
- No reusable finding-level result is available in this record.
Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.
Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.
Source supportStructured registry protocol metadata; no finding-level conclusion is generated.
Registration and recruitment status do not establish safety, efficacy, or regulatory approval.
Why this record appears here · 100% topic match
The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.
- Vision ageing · 100%Title contains controlled term: age-related macular degeneration. Abstract contains controlled term: age-related macular degeneration. Source terminology contains: age-related macular degeneration. Title supplies longevity context: age-related. Study type is explicitly identified as INTERVENTIONAL.
Automated source check 100% · update recency 50%. These figures help sort records; they are not medical ratings.